Yes they are partners. What I think is interesting about the PFE and Astellas partnership wrt enzalutamide is that if ZEN-3694 enhances the performance of enzalutamide, as has been suggested by management, it could bring both partners to the table and who knows what might happen then. Between PFE and Astellas they seem to have a lot of current programs that the Zenith and RVX IP might fit nicely into.